|
Name |
asperthrin B
|
| Molecular Formula | C26H29N3O5 | |
| IUPAC Name* |
3-hydroxy-9,9,16,16-tetramethyl-14-oxido-8-oxa-23,25-diaza-14-azoniaheptacyclo[17.5.2.01,17.03,15.04,13.07,12.019,23]hexacosa-4(13),5,7(12),10,14-pentaene-24,26-dione
|
|
| SMILES |
CC1(C)C=Cc2c(ccc3c2[N+]([O-])=C2C3(O)CC34NC(=O)C5(CCCN5C3=O)CC4C2(C)C)O1
|
|
| InChI |
InChI=1S/C26H29N3O5/c1-22(2)10-8-14-16(34-22)7-6-15-18(14)29(33)19-23(3,4)17-12-24-9-5-11-28(24)21(31)25(17,27-20(24)30)13-26(15,19)32/h6-8,10,17,32H,5,9,11-13H2,1-4H3,(H,27,30)/t17-,24+,25?,26?/m0/s1
|
|
| InChIKey |
QCZUWKYBDIHUEP-GVEWBGKASA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 463.53 | ALogp: | 2.3 |
| HBD: | 2 | HBA: | 5 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 104.9 | Aromatic Rings: | 8 |
| Heavy Atoms: | 34 | QED Weighted: | 0.455 |
| Caco-2 Permeability: | -5.043 | MDCK Permeability: | 0.00002780 |
| Pgp-inhibitor: | 0.985 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.388 | 20% Bioavailability (F20%): | 0.035 |
| 30% Bioavailability (F30%): | 0.011 |
| Blood-Brain-Barrier Penetration (BBB): | 0.609 | Plasma Protein Binding (PPB): | 83.38% |
| Volume Distribution (VD): | 1.057 | Fu: | 14.89% |
| CYP1A2-inhibitor: | 0.012 | CYP1A2-substrate: | 0.797 |
| CYP2C19-inhibitor: | 0.52 | CYP2C19-substrate: | 0.907 |
| CYP2C9-inhibitor: | 0.669 | CYP2C9-substrate: | 0.446 |
| CYP2D6-inhibitor: | 0.478 | CYP2D6-substrate: | 0.079 |
| CYP3A4-inhibitor: | 0.924 | CYP3A4-substrate: | 0.941 |
| Clearance (CL): | 0.78 | Half-life (T1/2): | 0.123 |
| hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.838 |
| Drug-inuced Liver Injury (DILI): | 0.814 | AMES Toxicity: | 0.384 |
| Rat Oral Acute Toxicity: | 0.765 | Maximum Recommended Daily Dose: | 0.856 |
| Skin Sensitization: | 0.021 | Carcinogencity: | 0.975 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.832 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005468 | ![]() |
0.771 | D0V4WD | ![]() |
0.212 | ||
| ENC004945 | ![]() |
0.739 | D0P0HT | ![]() |
0.212 | ||
| ENC004944 | ![]() |
0.739 | D06YFA | ![]() |
0.210 | ||
| ENC002536 | ![]() |
0.676 | D0C7JF | ![]() |
0.209 | ||
| ENC002534 | ![]() |
0.676 | D08UGJ | ![]() |
0.209 | ||
| ENC002366 | ![]() |
0.676 | D05AFR | ![]() |
0.209 | ||
| ENC004942 | ![]() |
0.646 | D06HBQ | ![]() |
0.209 | ||
| ENC002052 | ![]() |
0.593 | D06XZW | ![]() |
0.208 | ||
| ENC002538 | ![]() |
0.583 | D0N0RU | ![]() |
0.206 | ||
| ENC002704 | ![]() |
0.576 | D02JNM | ![]() |
0.205 | ||